Destiny Pharma Result of Annual General Meeting

Link to Full Article

Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.

The full text of each resolution was included in the notice of the meeting, which was made available on the Company’s website and posted to shareholders on 4th May 2021. The results for the resolutions will shortly be available on the Investors section of the Company’s website,

Nick Rodgers, Chairman of Destiny Pharma, commented:

“It has been a transformational last six months for Destiny Pharma. We recently delivered excellent Phase 2b data from our XF-73 nasal gel clinical study for the prevention of post-surgical infections and have now started talking to regulators regarding possible Phase 3 clinical plans. Also, we expanded our pipeline through the acquisition of NTCD-M3 to take it through its Phase 3 clinical study. NTCD-M3 has the potential to become the leading treatment for C. difficile infections, targeting a market that is forecast to grow to $1.7 billion by 2026. We remain committed to developing our novel products that prevent infections and look forward to delivering further progress and another successful year.”

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440 

Optimum Strategic Communications 
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789 

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information on the company, please visit